Review decision - August 2015

Review of NICE Technology Appraisal Guidance No. 288; Dapagliflozin for the treatment of type 2 diabetes

The Institute was proposing that the guidance should be partially updated in relation to the use of dapagliflozin in triple therapy regimens (recommendation 1.3 only).

After consideration of all of the comments received during the Review Consultation, the Technology Appraisals programme has decided to proceed with this proposal.

Consequently, TA288 will be partially updated. This update will focus on the use of dapagliflozin in triple therapy regimes and will be carried out via the Single Technology Appraisal (STA) process.

August 2015

This page was last updated: